+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Colorectal Cancer - Pipeline Review, H2 2018

  • ID: 4726721
  • Drug Pipelines
  • December 2018
  • Region: Global, Global
  • 2548 Pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Alligator Bioscience AB
  • Ascelia Pharma AB
  • BioXpress Therapeutics SA
  • Cellestia Biotech AG
  • Enochian Biosciences Inc
  • MORE

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

This latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 28, 157, 178, 17, 204, 39 and 13 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 35 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 3SBio Inc
  • Alligator Bioscience AB
  • Ascelia Pharma AB
  • BioXpress Therapeutics SA
  • Cellestia Biotech AG
  • Enochian Biosciences Inc
  • MORE
  • Introduction
  • Colorectal Cancer - Overview
  • Colorectal Cancer - Therapeutics Development
  • Colorectal Cancer - Therapeutics Assessment
  • Colorectal Cancer - Companies Involved in Therapeutics Development
  • Colorectal Cancer - Drug Profiles
  • Colorectal Cancer - Dormant Projects
  • Colorectal Cancer - Discontinued Products
  • Colorectal Cancer - Product Development Milestones
  • Appendix

List of Tables
Number of Products under Development for Colorectal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2018
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2018
Colorectal Cancer - Pipeline by 4SC AG, H2 2018
Colorectal Cancer - Pipeline by Aadi Bioscience Inc, H2 2018
Colorectal Cancer - Pipeline by AB Science SA, H2 2018
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2018
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2018
Colorectal Cancer - Pipeline by Abpro, H2 2018
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2018
Colorectal Cancer - Pipeline by ADC Therapeutics SA, H2 2018
Colorectal Cancer - Pipeline by Adhera Therapeutics, H2 2018
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2018
Colorectal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2018
Colorectal Cancer - Pipeline by Advanced BioDesign, H2 2018
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Colorectal Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018
Colorectal Cancer - Pipeline by Agenus Inc, H2 2018
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2018
Colorectal Cancer - Pipeline by Alkermes Plc, H2 2018
Colorectal Cancer - Pipeline by Alligator Bioscience AB, H2 2018
Colorectal Cancer - Pipeline by Allinky Biopharma SL, H2 2018
Colorectal Cancer - Pipeline by Almac Discovery Ltd, H2 2018
Colorectal Cancer - Pipeline by Alpine Immune Sciences Inc, H2 2018
Colorectal Cancer - Pipeline by ALX Oncology Inc, H2 2018
Colorectal Cancer - Pipeline by Amarin Corp Plc, H2 2018
Colorectal Cancer - Pipeline by amcure GmbH, H2 2018
Colorectal Cancer - Pipeline by Amgen Inc, H2 2018
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2018
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2018
Colorectal Cancer - Pipeline by Aphios Corp, H2 2018
Colorectal Cancer - Pipeline by Apogenix AG, H2 2018
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2018
Colorectal Cancer - Pipeline by Arcus Biosciences Inc, H2 2018
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2018
Colorectal Cancer - Pipeline by Arvinas Inc, H2 2018
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2018
Colorectal Cancer - Pipeline by Ascelia Pharma AB, H2 2018
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2018
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2018
Colorectal Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2018
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2018
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
Colorectal Cancer - Pipeline by Batu Biologics Inc, H2 2018
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2018
Colorectal Cancer - Pipeline by Bayer AG, H2 2018
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2018

List of Figures
Number of Products under Development for Colorectal Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 3-V Biosciences Inc
  • 3SBio Inc
  • 4SC AG
  • Aadi Bioscience Inc
  • AB Science SA
  • AbbVie Inc
  • AbGenomics International Inc
  • Abpro
  • Aclaris Therapeutics Inc
  • Adamed Sp z oo
  • ADC Therapeutics SA
  • Adhera Therapeutics
  • Aduro BioTech Inc
  • Advanced Accelerator Applications SA
  • Advanced BioDesign
  • Advenchen Laboratories LLC
  • Agency for Science, Technology and Research
  • Agenus Inc
  • AlfaSigma SpA
  • Alkermes Plc
  • Alligator Bioscience AB
  • Allinky Biopharma SL
  • Almac Discovery Ltd
  • Alpine Immune Sciences Inc
  • ALX Oncology Inc
  • Amarin Corp Plc
  • amcure GmbH
  • Amgen Inc
  • APEIRON Biologics AG
  • Apexigen Inc
  • Aphios Corp
  • Apogenix AG
  • Aposense Ltd
  • Arcus Biosciences Inc
  • Array BioPharma Inc
  • Arvinas Inc
  • Asana BioSciences LLC
  • Ascelia Pharma AB
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Aurobindo Pharma Ltd
  • B Cell Design SAS
  • Basilea Pharmaceutica Ltd
  • Batu Biologics Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • BeyondSpring Inc
  • Biocon Ltd
  • BioLineRx Ltd
  • Bionomics Ltd
  • Bionovis SA
  • Biosceptre International Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • Cancer Prevention Pharmaceuticals Inc
  • Canget BioTekpharma LLC
  • Cantargia AB
  • Carna Biosciences Inc
  • CaroGen Corp
  • CBT Pharmaceuticals Inc
  • CCRP Therapeutics GmbH
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Celleron Therapeutics Ltd
  • Cellestia Biotech AG
  • Cellix Bio Pvt Ltd
  • Celltrion Inc
  • Celyad SA
  • Checkmate Pharmaceuticals Inc
  • Chengdu Kanghong Pharmaceuticals Group Co
  • Chiome Bioscience Inc
  • Chipscreen Biosciences Ltd
  • ChoDang Pharm Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Chugai Pharmaceutical Co Ltd
  • Cinnagen Co
  • Cleveland BioLabs Inc
  • COARE Biotechnology Inc
  • Compugen Ltd
  • Conatus Pharmaceuticals Inc
  • Corvus Pharmaceuticals Inc
  • Cotinga Pharmaceuticals Inc
  • Cytlimic Inc
  • Daiichi Sankyo Co Ltd
  • Deciphera Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd
  • eFFECTOR Therapeutics Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Endor Technologies SL
  • Enochian Biosciences Inc
  • EntreChem SL
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • EpiThany Inc
  • Etubics Corp
  • Evelo Biosciences Inc
  • Exelixis Inc
  • Exicure Inc
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • Faron Pharmaceuticals Oy
  • Fate Therapeutics Inc
  • FLX Bio Inc
  • Fog Pharmaceuticals Inc
  • Forbius
  • Formosa Laboratories Inc
  • Forty Seven Inc
  • Fresenius SE & Co KGaA
  • Fujifilm Holdings Corporation
  • Fusion Antibodies plc
Note: Product cover images may vary from those shown
Adroll
adroll